Overview
- Defense Secretary Pete Hegseth announced on July 15, 2026 a program requiring annual testosterone screening for service members 30 and older and offering voluntary testosterone therapy to recipients.
- U.S. District Judge Ana Reyes took formal notice of the program on July 22, 2026 and ordered the government to explain why the same hormone treatments are readiness‑enhancing for some troops but disqualifying for transgender service members.
- The Pentagon has not published clinical protocols, diagnostic thresholds, monitoring rules, cost estimates, or deployment guidance for the screening and therapy plan, leaving implementation largely opaque.
- Medical experts and commentators warn that population‑wide screening departs from standard practice because testosterone diagnosis normally requires repeat morning tests and careful monitoring, and that replacement therapy carries risks such as reduced fertility and raised blood counts.
- The legal fight now moves quickly with expedited filings due in early August and a trial window set for January 2027, and the dispute could shape whether the transgender ban stands when lawmakers declined to codify it into statute.